Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
TERMINATED
NCT01580618
PHASE2/PHASE3

Tenecteplase (TNK) for Loculated Pleural Effusions in Patients With Malignancy

Sponsor: Kaiser Permanente

View on ClinicalTrials.gov

Summary

The objective of the study is to determine the safety and efficacy of TNK infusion for the treatment of loculated pleural effusions in patients with known malignancy compared to normal saline infusion.

Official title: TNK for Loculated Pleural Effusions in Patients With Malignancy

Key Details

Gender

All

Age Range

18 Years - 85 Years

Study Type

INTERVENTIONAL

Enrollment

20

Start Date

2008-01

Completion Date

2011-09

Last Updated

2026-04-14

Healthy Volunteers

No

Interventions

DRUG

normal saline

Injection of 60 ml normal saline twice a day for three days using the existing chest tube.

DRUG

TNK (Tenecteplase)

Injection of 4 mg of TNK with 59 ml normal saline into the existing chest tube twice a day for three days.

Locations (1)

Kaiser Foundation Hospital

Honolulu, Hawaii, United States